Zynex Recognized in Top 100 Public Companies by ColoradoBiz

         Zynex Recognized in Top 100 Public Companies by ColoradoBiz

PR Newswire

LONE TREE, Colo., June 19, 2017

LONE TREE, Colo., June 19, 2017 /PRNewswire/ -- Zynex (OTCQB: ZYXI), an
innovative medical technology company specializing in the manufacture and sale
of non-invasive medical devices for pain management, stroke rehabilitation,
neurodiagnostic equipment, cardiac and blood volume monitoring, announces
today that ColoradoBiz Magazine has recognized Zynex in Top100 Public
Companies in its May/June 2017 issue.


Zynex was ranked 90^th on 2016 revenue of $13.3 million up from 93^rd in 2015
on $11.6 million in revenue. Zynex previously announced estimated second
quarter 2017 revenue of $3.8 million and EBITDA of $650,000.

About ColoradoBiz

For over 44 years, state officials, company executives and business
professionals have looked to ColoradoBiz as the statewide voice of our
business community. We are committed not only to highlighting the people,
products, and companies that drive the economic future of our state, but
helping Colorado businesses connect with each other and market themselves more

About Zynex

Zynex, founded in 1996, markets and sells its own design of electrotherapy
medical devices used for pain management and rehabilitation; and the company's
proprietary NeuroMove device designed to help recovery of stroke and spinal
cord injury patients. Zynex is also developing a new blood volume monitor for
use in hospitals and surgery centers. For additional information, please
visit: Zynex.com.

Safe Harbor Statement

Certain statements in this release are "forward-looking" and as such are
subject to numerous risks and uncertainties. Actual results may vary
significantly from the results expressed or implied in such statements.
Factors that could cause actual results to materially differ from
forward-looking statements include, but are not limited to, the need to obtain
additional capital or augment our liquidity in order to continue our business,
the success of our international expansion efforts, our ability to engage
additional sales representatives and their success, the need to obtain FDA
clearance and CE marking of new products, the acceptance of new products as
well as existing products by doctors and hospitals, larger competitors with
greater financial resources, the need to keep pace with technological changes,
our dependence on the reimbursement from insurance companies for products sold
or rented to our customers, acceptance of our products by health insurance
providers, our dependence on third party manufacturers to produce our goods on
time and to our specifications, implementation of our sales strategy including
a strong direct sales force, the uncertain outcome of pending material
litigation, our ability to up-list to a larger exchange and other risks
described in our filings with the Securities and Exchange Commission including
the "Risk Factors" section of our Annual Report on Form 10-K for the year
ended December 31, 2016 as well as Forms 10-Q, 8-K and 8-K/A, press releases
and the Company's website.

Zynex, Inc.
(303) 703-4906


To view the original version on PR Newswire,


Website: http://Zynex.com
Press spacebar to pause and continue. Press esc to stop.